With 9K Tests Ordered, Foundation Medicine Highlights Utility in Patient Care and Drug Trials | GenomeWeb

Foundation Medicine said this week at the JP Morgan Healthcare Conference in San Francisco that it received orders for 9,000 of its FoundationOne next-generation sequencing cancer tests in 2013.

The company targets its test to both oncologists to help guide treatment of patients and also to pharmaceutical companies. During a presentation at the conference, CEO Michael Pellini highlighted the test's benefits to both groups and gave an overview of how the company plans to move forward in 2014 and the years ahead.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.